Why the study?
Does Idarubicin induce complete remission in adults with refractory or relapsed acute leukemia?
Does Idarubicin induce complete remission in adults with refractory or relapsed acute leukemia?
Idarubicin shows preliminary activity in inducing complete remission in adults with refractory or relapsed acute leukemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for idarubicin in refractory acute leukemia; prospective trials needed before any practice consideration.
Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.
No takes yet. Share an insight, caveat, or question.
Carella et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: